Scott Taylor, MD
Internal Medicine · Idaho Falls, IDNPI 1861542326
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Amgen at 35.8% of the total. Reporting peaked in 2023 at $1,196 and has fallen 56.8% since, to $517 in 2025. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$485
- GSK$308
- Novo Nordisk$289
- Boehringer Ingelheim$225
- AstraZeneca$164
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,899100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 140 | $1,760 |
| AbbVie(2 entities) | 24 | $485 |
| GSK | 21 | $308 |
| Novo Nordisk | 19 | $289 |
| Boehringer Ingelheim | 14 | $225 |
| AstraZeneca | 11 | $164 |
| Lilly USA, LLC | 12 | $162 |
| Astellas Pharma US Inc | 7 | $161 |
| Procept Biorobotics Corporation | 2 | $159 |
| Pfizer | 9 | $128 |
| Medtronic(2 entities) | 7 | $113 |
| Mylan Specialty L.p. | 6 | $108 |
| Penumbra, Inc. | 1 | $107 |
| Novartis | 5 | $100 |
| Johnson & Johnson | 6 | $91 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Edwards Lifesciences | 2 | $41 |
| Abbott | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Bayer | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Merck | 2 | $29 |
| Kerecis Limited | 2 | $28 |
| Recor Medical Inc | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| GE HealthCare | 1 | $26 |
| Viatris Specialty LLC | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$107
How this compares
$4,918 in reported general payments places this provider in the 95th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $154,096 |
| ActemraTocilizumab | 11 | $47,285 |
| MounjaroTirzepatide | 40 | $39,779 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,893 |
| XareltoRivaroxaban | 16 | $15,407 |
| OzempicSemaglutide | 14 | $12,987 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,855 |
| FarxigaDapagliflozin Propanediol | 11 | $9,770 |
| PremarinEstrogens, Conjugated | 13 | $8,770 |
| TrulicityDulaglutide | 11 | $8,090 |
| Levothyroxine Sodium | 290 | $3,444 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,307 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 83 | $2,982 |
| Omeprazole | 290 | $2,901 |
| Ondansetron OdtOndansetron | 23 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $128 | $162,866191 claims |
| Lilly USA, LLCMounjaro, Trulicity | $162 | $47,87051 claims |
| Johnson & JohnsonXarelto | $91 | $15,40716 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $308 | $14,16226 claims |
| Novo NordiskOzempic | $289 | $12,98714 claims |
| AstraZenecaFarxiga | $164 | $9,77011 claims |
| AbbVieSynthroid | $485 | $1,60148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Idaho Falls
- Susan WachterIdaho Falls$22K
- Ahmed MahmoodIdaho Falls$21K
- Kevin PrierIdaho Falls$6K
- Brady CookIdaho Falls$6K
- Johnathan LiljenquistIdaho Falls$525
- Leland KrantzIdaho Falls$447
- Alan AvondetIdaho Falls$411
- Margaret BakerIdaho Falls$403
- Allen SwansonIdaho Falls$303
- Sherwin D'souzaPocatello$543K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.